Ibogaine and Psilocybin in Brain Injury: Different Mechanisms, Different Possibilities

Interest in psychedelic medicine for traumatic brain injury has accelerated rapidly in recent years, with ibogaine and psilocybin emerging as two of the most promising compounds under investigation. Although research remains in its early stages, the findings reported to date have generated considerable excitement, raising the possibility that psychedelic medicines could fundamentally reshape how we approach recovery after brain injury.

Despite often being grouped together under the broad label of "psychedelics," ibogaine and psilocybin are fundamentally different medicines. They act through distinct pharmacological pathways, influence different biological systems, and may ultimately support recovery through different mechanisms. While there is undoubtedly considerable overlap, both appear capable of promoting neuroplasticity and psychological change, the emerging evidence suggests they may each occupy unique positions within neurorehabilitation. Psilocybin has been most strongly associated with enhancing functional brain network flexibility and psychological adaptation, whereas ibogaine is increasingly being investigated for its potential effects on structural brain repair, neurotrophic signalling, remyelination, and metabolic recovery.

As research continues to evolve, it is becoming increasingly plausible that the future of psychedelic neurorehabilitation will involve understanding not only whether these medicines work, but how they work, and which patients are most likely to benefit from each. This article explores the current evidence supporting both compounds and examines how their differing mechanisms may shape their future roles in the treatment of brain injury.

Neuroplasticity: Similar Destination, Different Routes

Neuroplasticity has become one of the defining concepts in modern psychedelic research. Both psilocybin and ibogaine have demonstrated the ability to promote forms of neural plasticity, but the mechanisms through which they appear to achieve this are notably different. 

Psilocybin primarily exerts its effects through activation of the serotonin 5-HT2A receptor. This initiates intracellular signalling cascades that increase brain-derived neurotrophic factor (BDNF), stimulate dendritic spine formation, and promote the formation of new synaptic connections. Rather than creating entirely new neural systems, these processes appear to strengthen communication within existing networks, allowing the brain to become more flexible in how it processes information, emotions, and behaviour.

Ibogaine also appears to increase BDNF, but its neurobiological profile extends considerably further. Experimental research suggests ibogaine also upregulates glial-derived neurotrophic factor (GDNF) and nerve growth factor (NGF), two neurotrophic factors with established roles in neuronal survival, axonal maintenance, and tissue repair. GDNF has attracted particular interest because of its involvement in protecting vulnerable neurons and supporting recovery following neurological injury. 

While both compounds may ultimately increase the brain's capacity for change, the nature of that change may differ. Psilocybin appears to promote greater flexibility within neural networks, whereas ibogaine may additionally support the biological processes required for structural recovery.

Functional Reorganisation versus Structural Brain Change

Modern neuroimaging has provided important insights into how psychedelics alter the injured brain. However, the types of changes reported for psilocybin and ibogaine appear to diverge in meaningful ways.

Human studies of psilocybin consistently demonstrate changes in functional connectivity. Brain networks that ordinarily communicate in predictable patterns become temporarily more flexible, allowing increased communication between regions that are normally more segregated. Activity within the default mode network is reduced, while communication across multiple large-scale brain networks becomes more dynamic. These functional changes are believed to underpin many of psilocybin's therapeutic effects, including increased cognitive flexibility, emotional processing, and psychological adaptation.

Ibogaine has also demonstrated widespread changes in functional connectivity, but recent research has extended beyond network dynamics alone. In studies involving military veterans with traumatic brain injury, investigators observed increased cortical thickness across multiple cortical regions, enlargement of several subcortical structures, reductions in estimated brain age, increased regional cerebral blood flow, and reorganisation of large-scale functional networks following treatment. Neuropsychological testing also demonstrated improvements across processing speed, executive functioning, attention, and memory.

White Matter Repair and Remyelination

Much of the long-term disability following traumatic brain injury arises not from the death of neurons alone, but from damage to white matter pathways that connect different regions of the brain. Diffuse axonal injury disrupts communication between neural networks, while loss of myelin slows the transmission of electrical signals and contributes to many of the cognitive difficulties experienced after brain injury, including slowed processing speed, mental fatigue, and impaired executive functioning.

One of the more distinctive features of ibogaine research is its potential relationship with remyelination. Preclinical studies have demonstrated increased expression of genes and proteins involved in myelin repair, including markers associated with oligodendrocyte function and myelin basic protein synthesis. These findings suggest that ibogaine may influence the restoration of white matter integrity following neurological injury.

By comparison, there is currently little evidence that psilocybin directly promotes remyelination. Its effects appear to be centred on enhancing synaptic plasticity and facilitating more adaptive communication between existing neural circuits rather than repairing the structural components of white matter.

Beyond Plasticity: Energy Metabolism, Blood Flow and Neuroinflammation

Recovery following brain injury requires considerably more than simply increasing neuroplasticity. The injured brain often remains metabolically compromised for months or years after the initial trauma, with persistent neuroinflammation, impaired cerebral blood flow, mitochondrial dysfunction, and reduced cellular energy production contributing to ongoing symptoms.

Ibogaine appears to influence several of these biological systems simultaneously. Experimental studies suggest that ibogaine increases enzymes involved in ATP production and glucose metabolism, potentially improving the energy available to metabolically vulnerable neurons. Human imaging studies have demonstrated increases in regional cerebral blood flow following treatment, while laboratory studies suggest modulation of inflammatory pathways through reductions in pro-inflammatory cytokines and alterations in microglial activity. Together, these mechanisms may create a biological environment more conducive to neural repair and long-term recovery.

Psilocybin also demonstrates anti-inflammatory effects and has been shown to influence immune signalling in experimental models. However, the current literature has focused less on metabolic restoration or vascular changes, instead emphasising alterations in functional connectivity, emotional processing, learning, and behavioural flexibility.

This distinction may prove important when considering chronic brain injury, where ongoing metabolic dysfunction and neuroinflammation frequently persist long after the original injury has occurred.

Distinct Therapeutic Roles in Brain Injury

Ibogaine currently appears to hold the greatest therapeutic potential for brain injury. While both medicines appear capable of facilitating profound emotional processing and promoting neuroplasticity, ibogaine possesses a remarkably broad neurobiological profile. Beyond its psychological effects, emerging evidence suggests it may influence neurotrophic signalling, remyelination, cerebral blood flow, brain energy metabolism, neuroinflammation, and, perhaps most strikingly, measurable structural changes within the brain. If these findings continue to be replicated in larger controlled studies, they could represent a fundamentally different therapeutic proposition to anything currently available within neurorehabilitation.

Psilocybin may prove particularly valuable for individuals whose recovery is dominated by trauma, depression, anxiety, identity reconstruction, or psychological adjustment following brain injury. Its shorter duration and comparatively more manageable therapeutic experience may also make it a more accessible introduction to psychedelic-assisted therapy for many individuals.

Equally, the intensity of a full dose ibogaine experience should not be underestimated. The treatment often involves 24 hours or more of continuous psychological, emotional, and existential processing, which can be profoundly challenging as well as deeply therapeutic. Not every individual will be ready, or medically appropriate for such an experience. This raises an interesting possibility for future research: whether ibogaine microdosing might allow some of ibogaine's proposed neurobiological benefits to accumulate gradually, while reducing the psychological intensity associated with a full flood dose. Although early case reports are encouraging, we do not yet know whether microdosing produces the same structural brain changes that have been reported following full-dose treatment, and this represents an important area for future investigation.

Ultimately, I suspect the future of psychedelic neurorehabilitation will not revolve around choosing between ibogaine and psilocybin, but rather understanding which medicine is most appropriate for which patient, at which stage of recovery. Both compounds have the potential to transform how we think about recovery after brain injury.

References

Blest-Hopley, G., Pasculli, G., Ruffell, S. G., Tsang, W., Emmanuel, O., Pate, K. M., ... & Carhart-Harris, R. (2025). Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. Frontiers in psychiatry, 16, 1594307.                       https://doi.org/10.3389/fpsyt.2025.1594307

Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., ... & Williams, N. R. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature medicine, 30(2), 373-381.                                                                                      https://doi.org/10.1038/s41591-023-02705-w

Lissemore, J. I., Chaiken, A., Cherian, K. N., Buchanan, D., Espil, F., Keynan, J. N., ... & Williams, N. R. (2025). Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury. Nature Mental Health, 3(8), 918-931. https://doi.org/10.1038/s44220-025-00463-x

Tabaac, B. J., Carhart-Harris, R. L., & Yung, T. (2026).Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: A case series. Frontiers in Pharmacology, 17, 1840956. https://doi.org/10.3389/fphar.2026.1840956